Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global CAR T-Cell Therapy Market 2030 by Drug type, Indication, Target Antigen, End-user and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints" report has been added to ResearchAndMarkets.com's offering.
The healthcare industry is setting its sights on the revolutionary advancements in cancer treatment as the global CAR T-cell therapy market is anticipated to experience an astounding growth spurt. According to a new research publication, the market size, which stood at USD 8.2 billion in 2022, is estimated to reach USD 11.2 billion by 2030. This growth trajectory reflects a robust compound annual growth rate (CAGR) of 23.8% during the forecast period.
The market dynamics are significantly influenced by the remarkable efficacy of CAR T-cell therapy in treating certain challenging cancer types, particularly hematological malignancies. The ongoing success in clinical trials and the number of therapies receiving regulatory approvals highlight the driving forces behind this unprecedented market expansion.
North America continues to lead the charge in this domain, with the United States at the forefront, benefiting from high healthcare expenditure, groundbreaking FDA approvals, and substantial advancements in treatment procedures. Awareness campaigns and education initiatives further contribute to the robust market landscape seen in this region.
Asia-Pacific Region Exhibits Highest Growth
Stepping into the global arena, the Asia-Pacific region is anticipated to chart the highest growth rate, fueled by impressive strides in the healthcare industry and increased government spending on research and development. China is emerging as a trailblazer within this regional market, marked by a surge in clinical trials focusing on CAR T-cell therapy.
The comprehensive report delineates the market segmented by drug type, indication, target antigen, and end-user, further emphasizing the competitive landscape and strategic movements by major healthcare players.
- Market Segmentation Enhances Precision: The insightful segmentation caters to a detailed understanding of various aspects of the market including prominent drugs like KYMRIAH, YESCARTA, and others.
- Robust Product Pipeline Spurs Innovation: A strong product pipeline stimulating market demand underpins the advancements forecasted for this sector.
- Expert Analysis Reveals Key Market Trends: The report unveils expert analytical insights that chart the course of the market's trajectory, carefully evaluating patterns and growth stimulators.
Healthcare providers, patients, and investors can harness the granular data and projections delineated in the report to strategize for upcoming market trends. Furthermore, stakeholders can leverage the in-depth analysis that the report offers to understand the evolving landscape and align their business models accordingly.
As the global CAR T-cell therapy market braces for a period of significant growth, propelled by technological innovations and a heightened focus on personalized medicine, the detailed report emerges as a critical resource for those looking to make informed decisions in the healthcare sector.
Companies Mentioned
- Pfizer, Inc.
- Cellectis
- Caribou Biosciences, Inc.
- Celyad Oncology
- Merck & Co., Inc.
- Celgene Corporation
- Juno Therapeutics, Inc.
- Sorrento Therapeutics, Inc.
- Bluebird Bio, Inc002E
- Gilead Sciences, Inc. (Kite Pharma Inc.)
- Cartesian Therapeutics, Inc
- Bristol-Myers Squibb
- Miltenyi Biotech
- Autolus Therapeutics
- Novartis AG
For more information about this report visit https://www.researchandmarkets.com/r/pxjudz
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
